{"id":"W2957103174","doi":"10.1200/jco.2019.37.15_suppl.7005","title":"ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nilotinib; Imatinib; Gastroenterology; Imatinib mesylate; Surgery; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009355021,0.0003356737,0.0007788631,0.000180857,0.0001598503,0.0004027132,0.0003740831,0.0004576735,0.003926205],"category_scores_gemma":[0.0009818733,0.0001143873,0.0004561626,0.0001879793,0.0001573485,0.000573977,0.0002888682,0.0008659087,0.000727525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003467267,"about_ca_system_score_gemma":0.0002453026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003028761,"about_ca_topic_score_gemma":0.0008984854,"domain_scores_codex":[0.9996606,0.0001505292,0.00002577944,0.00007173089,0.00003940594,0.00005195269],"domain_scores_gemma":[0.9994918,0.0001064498,0.000207285,0.00004785489,0.00002081077,0.0001256366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6256832,0.007392164,0.04138491,0.001102966,0.001058603,0.0005224533,0.0002250714,0.002220831,0.024511,0.0002620281,0.008426552,0.2872101],"study_design_scores_gemma":[0.1770066,0.3599976,0.4197313,0.000213386,0.001604228,0.002447015,0.0001240759,0.003178071,0.01201318,0.000592659,0.02300989,0.00008197548],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879253,0.004694155,0.0005605154,0.000286945,0.00004871034,0.0003978751,0.00252986,0.00009044586,0.003466074],"genre_scores_gemma":[0.9946129,0.0005174833,0.000367163,0.0002031019,0.00004532543,0.0002390607,0.002033985,0.00001480216,0.0019662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003926205,"threshold_uncertainty_score":0.01313448,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05632872461739119,"score_gpt":0.3928476265998512,"score_spread":0.33651890198246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}